title: [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and  the correlation among them].
abstract: OBJECTIVE
  To study the expression of PTEN, p53 and epidermal growth factor receptor (EGFR) in the molecular subtypes of breast carcinoma and to evaluate the correlations with triple-negative breast cancer.
  
  
  METHODS
  Immunohistochemical MaxVision(TM) method was used to detect the expression of PTEN, p53, EGFR, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in 291 cases of infiltrating ductal carcinoma of breast.
  
  
  RESULTS
  The positive expression of PTEN, p53 and EGFR protein in breast carcinoma was 57.0%, 57.0% and 38.5%, respectively, which were significantly different from those in benign breast diseases (P<0.05). The expression of PTEN or EGFR in breast cancer was correlated with tumor size, histological grade, lymph node metastasis, TNM stage, ER and HER2 status (P<0.05); the expression of p53 was correlated with tumor size, histological grade and ER status (P<0.05). The difference of positive expression rates of PTEN, p53 and EGFR protein among different subtypes including luminal A, luminal B (HER2-), luminal B (HER2+), HER2 over-expression and triple-negative was statistically significant (P<0.05). There were close correlations among PTEN, p53 and EGFR in the triple-negative subtype (P<0.05).
  
  
  CONCLUSIONS
  Low expression of PTEN and high expression of EGFR and p53 are observed in triple-negative breast cancer, which may synergistically contribute to the pathogenesis of triple-negative breast cancer.
authors.affiliation: Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China lixinjunhe@163.com.
authors.forename: Xinjun
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Science and Education, Binzhou People's Hospital, Binzhou Shandong 256610, China.
authors.forename: Qingyuan
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China.
authors.forename: Limei
authors.initials: L
authors.lastname: Fu
authors.affiliation: Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China.
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.affiliation: Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China.
authors.forename: Xuemei
authors.initials: X
authors.lastname: Yu
mesh_terms: D001943:Breast Neoplasms / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D051059:PTEN Phosphohydrolase; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C495901:TP53 protein, human; C508053:ERBB2 protein, human; C494929:PTEN protein, human